Inflammatory mechanisms of pancreatic β-cell dysfunction and therapeutic strategies in type 2 diabetes mellitus: a narrative review. (PubMed, J Diabetes Metab Disord) - Sep 26, 2026 - "Randomised trials have reported improvements in glycaemic control or β-cell functional indices with anakinra, salsalate, liraglutide, dapagliflozin, thiazolidinediones, and short-term intensive insulin therapy...Canakinumab did not reduce new-onset diabetes or provide sustained glycaemic improvement, whereas regenerative and gene-editing approaches remain experimental...IL-1 pathway modulation warrants further investigation, whereas regenerative and gene-based approaches remain experimental. Patient stratification based on β-cell functional status and inflammatory profiles requires prospective validation before clinical implementation."
Journal • Review • Diabetes • Inflammation • Metabolic Disorders • Type 2 Diabetes Mellitus
|
|
Ilia Andreevich Rakhov; Irina Georgievna Danilova; Ksenia Viktorovna Sokolova; Tianjiao Li
|